Short Interest in Agile Therapeutics Inc (AGRX) Decreases By 24.9%

Agile Therapeutics Inc (NASDAQ:AGRX) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 844,663 shares, a decrease of 24.9% from the February 15th total of 1,125,414 shares. Based on an average trading volume of 362,532 shares, the short-interest ratio is currently 2.3 days. Currently, 3.6% of the shares of the company are short sold.

Several research firms have issued reports on AGRX. ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 11th. Maxim Group restated a “buy” rating and issued a $3.00 price objective on shares of Agile Therapeutics in a research note on Monday, February 11th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Agile Therapeutics in a research note on Friday, January 11th.

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after buying an additional 18,038 shares during the period. Geode Capital Management LLC boosted its stake in shares of Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares during the period. Fosun International Ltd acquired a new stake in shares of Agile Therapeutics during the third quarter worth about $180,000. Acadian Asset Management LLC boosted its stake in shares of Agile Therapeutics by 260.7% during the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 226,255 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Agile Therapeutics by 54.3% during the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 430,907 shares during the period. Institutional investors and hedge funds own 42.15% of the company’s stock.

Shares of AGRX opened at $1.61 on Friday. Agile Therapeutics has a fifty-two week low of $0.23 and a fifty-two week high of $3.24. The stock has a market cap of $57.41 million, a PE ratio of -2.78 and a beta of 0.36.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. Research analysts expect that Agile Therapeutics will post -0.65 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2019/03/16/short-interest-in-agile-therapeutics-inc-agrx-decreases-by-24-9.html.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply